It has been shown that PD-L1 is expressed in several malignancies, including breast cancer.3 In addition, it has been suggested that higher PD-L1 expression in tumor cell membrane versus stromal immune cells is associated with different clinicopathological features and clinical outcomes in multiple different tumor types. This evidence concerns the gene CD274 and breast carcinoma.